Skip to main content

Table 2 Akaike Information Criterion (AIC) values for the Cox models, First 6 months of follow-up (464 patients)

From: Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study

Model   HR (95% CI) p value AIC*
RECIST Partial response 1   575.762
  Stable disease 2.29 (1.06-4.94) 0.03  
  Progressive disease 18.48 (8.41-40.59) <10−4  
UCSTS per 10% difference 1.21 (1.16-1.26) <10−4 578.585
  1. The analysis was routinely adjusted on histology and cancer spread. Sex and chemotherapy doublet were proposed to the model but not kept at the final step. The analysis was stratified on ECOG-PS and hospital.
  2. *In the model with RECIST, −2log likelihood = 563.762 with 6 degrees of freedom. In the model with UCSTS changes, −2log likelihood = 568.585 with 5 degrees of freedom.
  3. p = 0.03.
  4. HR, hazard ratio; 95% CI, 95% confidence interval; RECIST, Response Evaluation Criteria in Solid Tumors; UCSTS, unidimensional continuous-scale tumour size.